PCR-electrospray ionization mass spectrometry: the potential to change infectious disease diagnostics in clinical and public health laboratories.

The Journal of Molecular Diagnostics : JMD
Donna M WolkVicki H Wysocki

Abstract

During the past 20 years, microbial detection methods that are genetically based, such as real-time PCR and peptide nucleic acid fluorescent hybridization, coexisted with traditional microbiological methods and were typically based on the identification of individual genetic targets. For these methods to be successful, a potential cause of infection must be suspected. More recently, multiplex PCR and multiplex RT-PCR were used to enable more broad-range testing based on panels of suspected pathogens. PCR-electrospray ionization mass spectrometry (PCR-ESI/MS) has emerged as a technology that is capable of identifying nearly all known human pathogens either from microbial isolates or directly from clinical specimens. Assay primers are strategically designed to target one or more of the broad pathogen categories: bacterial, mycobacterial, fungal, or viral. With broad-range amplification followed by detection of mixed amplicons, the method can identify genetic evidence of known and unknown pathogens. This unique approach supports a higher form of inquiry, asking the following question: What is the genetic evidence of known or unknown pathogens in the patient sample? This approach has advantages over traditional assays that commonly...Continue Reading

References

Aug 23, 2001·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·L H TaylorM E Woolhouse
Mar 11, 2005·Emerging Infectious Diseases·Rangarajan SampathDavid J Ecker
May 25, 2005·Proceedings of the National Academy of Sciences of the United States of America·David J EckerSteven A Hofstadler
May 2, 2007·Annals of the New York Academy of Sciences·Rangarajan SampathDavid J Ecker
Jul 28, 2007·Virology·Mark W EshooDavid J Ecker
Feb 15, 2008·Journal of Clinical Microbiology·James C HannisSteven A Hofstadler
Jun 4, 2008·Nature Reviews. Microbiology·David J EckerSteven A Hofstadler
Mar 20, 2009·Journal of Clinical Microbiology·Kristine M HujerRobert A Bonomo
Apr 24, 2010·Molecular and Cellular Probes·Rebecca J Grant-KleinChris A Whitehouse
Jul 29, 2010·Epidemiology and Infection·T LeslieR Kakar
Sep 24, 2010·Journal of Clinical Microbiology·David MetzgarPatrick J Blair
Oct 26, 2010·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·S EmonetJ Schrenzel
Dec 22, 2010·Expert Review of Molecular Diagnostics·Varough M DeydeLarisa V Gubareva
Feb 22, 2011·FEMS Immunology and Medical Microbiology·Paul StoodleySandeep Kathju
Apr 6, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Andrea EndimianiRobert A Bonomo

❮ Previous
Next ❯

Citations

Jun 5, 2014·BMC Infectious Diseases·Cynthia SantamariaMomar Ndao
Nov 19, 2014·Future Microbiology·Rayane RafeiMarie-Laure Joly-Guillou
Aug 16, 2014·The Journal of Maternal-fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians·Roberto RomeroYeon Mee Kim
Sep 6, 2014·The Journal of Maternal-fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians·Roberto RomeroYeon Mee Kim
Feb 13, 2013·Infectious Disease Clinics of North America·Charlotte A Gaydos
Sep 17, 2015·Analytical Chemistry·Matthew W FosterM Arthur Moseley
May 13, 2014·BioMed Research International·Elena Jordana-LluchElisa Martró
Mar 19, 2014·Frontiers in Cellular and Infection Microbiology·Marc Lecuit, Marc Eloit
Jun 18, 2016·Health Security·Norman A DoggettSegaran Pillai
May 21, 2017·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Heimo LaglerMichael Ramharter
Feb 7, 2017·Molecular & Cellular Proteomics : MCP·Todd M Greco, Ileana M Cristea
Jan 1, 2013·Infectious Diseases·Balkis A TalipWilliam J Snelling
Oct 30, 2015·Journal of the American Society for Mass Spectrometry·Gelio AlvesYi-Kuo Yu
Jan 17, 2015·Genome Medicine·Pierre-Edouard FournierDidier Raoult
Dec 24, 2019·Expert Review of Respiratory Medicine·Jean-Philippe BoucharaGilles Nevez
Jun 4, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Katarzyna PauterBogusław Buszewski
Feb 19, 2015·Current Opinion in Infectious Diseases·Thilini L Basnayake, Grant W Waterer
Feb 3, 2015·Expert Review of Anti-infective Therapy·Luisa BarzonGiorgio Palù
Jan 10, 2018·Analytical and Bioanalytical Chemistry·Michael BeverlyOlga Slack
May 22, 2016·Infectious Disease Clinics of North America·Andrea Endimiani, Michael R Jacobs
Oct 12, 2016·Microbiology Spectrum·Karen C Carroll, La'tonzia L Adams
May 23, 2021·Clinics in Laboratory Medicine·Christopher R Cox, Rebecca M Harris
Sep 4, 2020·Journal of the American Society for Mass Spectrometry·Iqbal Mahmud, Timothy J Garrett

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
Biosensor
genotyping
electrophoresis
confocal microscopy

Software Mentioned

Biothreat
PLEX
NFDU
ID
ID Rapid
TIGER

Related Concepts

Related Feeds

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Biofilm & Infectious Disease

Biofilm formation is a key virulence factor for a wide range of microorganisms that cause chronic infections.Here is the latest research on biofilm and infectious diseases.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Biofilms

Biofilms are adherent bacterial communities embedded in a polymer matrix and can cause persistent human infections that are highly resistant to antibiotics. Discover the latest research on Biofilms here.

Campylobacteriosis (ASM)

Campylobacteriosis is caused by the bacteria Campylobacter jejuni and is a common cause of gastroenteritis in humans. Discover the latest research on Campylobacteriosis here.